Navigation Links
New Drug Application For Naloxegol Accepted By United States Food And Drug Administration
Date:11/19/2013

SAN FRANCISCO, Nov. 19, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) reported today that partner AstraZeneca announced that the United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for naloxegol, an investigational peripherally-acting mu-opioid receptor antagonist (PAMORA), which has been studied in opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, the most common side effect caused by chronic administration of prescription opioid pain medicines.

The NDA filing was based on comprehensive data from the core Phase III KODIAC programme, which is comprised of four clinical trials designed to investigate the safety and efficacy of naloxegol for the treatment of OIC. Two pivotal Phase III studies, KODIAC-04 (n=652) and KODIAC-05 (n=700), both 12-week, multicentre, randomized, double blind, placebo-controlled pivotal trials evaluated 12.5 mg and 25 mg doses of naloxegol, administered once-daily. KODIAC-07, a 12-week safety extension of KODIAC-04, and KODIAC-08 (n= 534) was an open-label controlled, randomized, 52-week, long-term safety trial.

Naloxegol has the potential to be the first once-daily oral PAMORA for patients with OIC in the United States. Naloxegol was developed using Nektar's oral small molecule polymer conjugate technology.

Naloxegol is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics. Under the terms of the amended license agreement, AstraZeneca will make a $70 million milestone payment to Nektar within five business days of acceptance of the NDA by the FDA.

About Naloxegol Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist (PAMORA), which has been specifically designed for the treatment o
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
2. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
3. Bio-AMD, Inc.; Patent Application for Cartridge Test Cap
4. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
5. Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
8. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
9. Philips demonstrates innovations in nuclear medicine imaging with a comprehensive portfolio of NM applications for IntelliSpace Portal
10. Clinical Safety Data for ChromaDex®s Patented pTeroPure® (pterostilbene) Released at 6th World Congress on Polyphenols Applications in Paris
11. UltraTape announces Cleanroom Labels for Cryogenic Laboratory applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Larry J. ... CVS ), will speak before the National Press Club ... discuss the company,s recent move to stop selling tobacco products ... the future of health. "Dramatic changes in our ... care providers and government," Merlo has said. "CVS Health has ...
(Date:9/19/2014)... 19, 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ... received and approved all parts required to build ... begun to manufacture the new PCT-based instrument system.  ... ready for shipment by mid-October and that additional ... a rate of about one per week thereafter.  ...
(Date:9/19/2014)... MINNEAPOLIS and ORLANDO, Fla. ... data supporting Inspire therapy continues to grow, with the ... paper published on-line in Otolaryngology – Head ... therapy causes a worsening of both objective and subjective ... to directly attribute Inspire therapy for the reduction in ...
Breaking Medicine Technology:CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
(Date:9/21/2014)... September 21, 2014 The Illinois ... will host a statewide symposium ( tinyurl.com/ILBHC14 ) ... and their Families. Sponsored by the VNA Foundation, ... Cash Grant, and Health & Disability Advocates, the ... the Hilton Hotel in Springfield, IL. The ...
(Date:9/21/2014)... SUNDAY, Sept. 21, 2014 (HealthDay News) -- Young women ... and know which foods they should eat. But they ... nutritional choices, according to a new study. ... the University of Illinois,s Peer Education Exercising and Eating ... what would they choose to eat if they were ...
(Date:9/21/2014)... September 21, 2014 Market ... (CAS 49562-28-9) Industry, 2009-2019 is a professional ... Chinese Fenofibrate (CAS 49562-28-9) industry. The report ... (CAS 49562-28-9) including its classification, application and ... China’s top manufacturers of Fenofibrate (CAS 49562-28-9) ...
(Date:9/21/2014)... experienced review website in the global market, Top10BestSEOHosting.com, has ... that FatCow ( http://www.top10bestseohosting.com/go/FatCow.com/ ), GoDaddy and Bluehost are ... been a boom in websites in recent years, and ... the number of web hosting companies that offer a ... (Virtual Private Server) is the method of partitioning a ...
(Date:9/21/2014)... 2014 Faculty and staff at Garrison Forest ... in Owings Mills, Md., kicked off the academic year by ... GFS is the first independent school to receive the bands— ... even sleep patterns— as part of a pilot program with ... walking specialty chain. The Vivofit bands are just one tool ...
Breaking Medicine News(10 mins):Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News: College Women Can Use Food Strategies, Study Finds 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Top10BestSEOHosting.com: FatCow, GoDaddy And Bluehost Are The Best VPS Hosting Suppliers 2Health News:Garrison Forest School Leader in Independent School Wellness Programs 2
... to Participating in Conspiracy , WASHINGTON, Oct. 9 ... in connection with an alleged $2.3 million Medicare fraud ... that purported to specialize in providing injection and infusion ... A. Breuer, U.S. Attorney for the Eastern District of ...
... , PRINCETON, N.J., Oct. 5 In conjunction with its third quarter ... 21, 2009), Covance Inc. (NYSE: CVD ) is pleased to invite ... broadcast live over the Internet on Thursday, October 22, 2009 at 9:00 ... Quarter 2009 Earnings Webcast and Slide Presentation, When: ...
... researchers say , FRIDAY, Oct. 9 (HealthDay News) -- Human ... cases of a rare type of head and neck cancer, ... tumor that grows behind the nose and at the top ... of every 100,000 people in the United States. According to ...
... ... CMS-mandated Home Health Agency Satisfaction Reporting Set to Begin , , ... South Bend, IN (Vocus) October 9, ... and a new report released today finds an upward trend in overall home care ...
... ... 8th Annual Electronic Submissions Conference from November 17- 19, 2009 in San Diego, CA., ... Horsham, PA (Vocus) October 8, ... Electronic Submissions Conference from November 17- 19, 2009 in San Diego, CA., , , ...
... type 1 diabetes, widens net while increasing accuracy of ... A sophisticated computational algorithm, applied to a large ... conventional methods in assessing individual risk for type 1 ... M.D., Ph.D., director of the Center for Applied Genomics ...
Cached Medicine News:Health News:Detroit Clinic Owner, Doctor and Office Manager Indicted in Medicare Infusion Fraud Scheme 2Health News:Detroit Clinic Owner, Doctor and Office Manager Indicted in Medicare Infusion Fraud Scheme 3Health News:Detroit Clinic Owner, Doctor and Office Manager Indicted in Medicare Infusion Fraud Scheme 4Health News:HPV Tied to Rare Head-and-Neck Cancer 2Health News:Authoritative Report on Home Health Care Experiences Released By Press Ganey 2Health News:Authoritative Report on Home Health Care Experiences Released By Press Ganey 3Health News:DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 2Health News:DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 3Health News:Gene Data Tool Advances Prospects for Personalized Medicine 2Health News:Gene Data Tool Advances Prospects for Personalized Medicine 3
... LH Ovulation Predicting Test is a qualitative ... Hormone (hLH) in human urine to predict ... by the elevation of human luteinizing hormone ... period starts, hLH has a brief, significant ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
... The Shandon Varistain 24-4 ... stainer designed to offer simplicity ... cytology staining applications. It is ... load and continuous throughput. ...
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning....
Medicine Products: